Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592807 | 0.80 | MEN1 (0.40) | ALOX15HSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL2782043 | 0.76 | NOS2 (0.39) | BRPF1ALOX15HSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL2995811 | 0.76 | CA12 (0.52) | GAAMAPTLMNACA12CA9 | |
| SCHEMBL9208019 | 0.75 | ALOX15 (0.36) | BRPF1ALOX15HSD17B10ALDH1A1MEN1 | |
| SCHEMBL3153578 | 0.72 | ALDH1A1 (0.56) | ALOX15HSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL8806440 | 0.72 | MEN1 (0.41) | BRPF1ALOX15HSD17B10ALDH1A1MEN1 | |
| SCHEMBL4111485 | 0.71 | NOS2 (0.44) | BRPF1ALOX15HSD17B10ALDH1A1MEN1 | |
| SCHEMBL4203753 | 0.68 | ALDH1A1 (0.31) | ALDH1A1MAPTLMNA | |
| SCHEMBL4203755 | 0.68 | ALDH1A1 (0.31) | ALDH1A1MAPTLMNA | |
| SCHEMBL5730287 | 0.68 | BRPF1 (0.37) | BRPF1ALOX15HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | claimed |
| EP-2044071-A1 | OOXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-08 | — | — | EP | claimed |
| WO-2007147646-A1 | OXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | claimed |
| EP-2576536-B1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | UNIV QUEENSLAND (AU) | 2016-09-14 | — | — | EP | disclosed |
| US-9199976-B2 | Haematopoietic-prostaglandin D2 synthase inhibitors | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-12-01 | — | — | US | disclosed |
| US-8653076-B2 | Oxo-substituted imidazo[1,2B]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20130137684-A1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-05-30 | — | — | US | disclosed |
| EP-2576536-A2 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | The University of Queensland (AU) | 2013-04-10 | — | — | EP | disclosed |
| WO-2012142659-A1 | SITE-SELECTIVE MODIFICATION OF PROTEINS | BAKER IDI HEART AND DIABETES INSTITUTE HOLDINGS LIMITED (AU) | 2012-10-26 | — | — | WO | disclosed |
| US-8097627-B2 | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | Bayer Pharma AG (DE) | 2012-01-17 | — | — | US | disclosed |
| WO-2011150457-A2 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-12-08 | — | — | WO | disclosed |
| WO-2006066950-A2 | TRICYCLIC AMINOALCOHOLS, METHODS FOR PRODUCING THE SAME AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
| EP-1670458-A1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-21 | — | — | EP | disclosed |
| US-20060084652-A1 | Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2006-04-20 | — | — | US | disclosed |
| WO-2006027236-A1 | ALKYLIDENE TETRAHYDRONAPHTHALENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-03-16 | — | — | WO | disclosed |
| US-20050272823-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-08 | — | — | US | disclosed |
| US-20050222154-A1 | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-10-06 | — | — | US | disclosed |
| US-20050209324-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-09-22 | — | — | US | disclosed |
| US-20050171109-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-08-04 | — | — | US | disclosed |
| WO-2005034939-A1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | CDK2, CDK1, MAP4K2 | BRPF1 1503/4885ALOX15 3800/4885HSD17B10 4303/4885 |
| US-20060084652-A1 | Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | PTGES, PTGS1, PTGES2 | BRPF1 809/4885ALOX15 33/4885HSD17B10 113/4885 |
| US-20130137684-A1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | HPGDS, PTGES, PTGIS | BRPF1 778/4885ALOX15 23/4885HSD17B10 350/4885 |
| US-20050171109-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | TNF, DHPS, PTGES | BRPF1 921/4885ALOX15 70/4885HSD17B10 174/4885 |
| US-20050222154-A1 | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | DHPS, TNF, IL1B | BRPF1 1008/4885ALOX15 44/4885HSD17B10 278/4885 |
| US-20050272823-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | DHPS, TNF, PTGES | BRPF1 1304/4885ALOX15 44/4885HSD17B10 177/4885 |
| US-20050209324-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | TNF, DHPS, PTGES | BRPF1 921/4885ALOX15 70/4885HSD17B10 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.